CMAC’s vision is to revolutionise the way pharmaceuticals and high-value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, postdocs, and more than 45 PhD students, as well as an experienced support team.
17 November 2020
BOOK YOUR PLACE NOW